Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26123165 | 0.83 | NPSR1 (0.50) | ALDH1A1LMNASMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL1752937 | 0.81 | CSNK1D (0.47) | ALDH1A1LMNASMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL1752868 | 0.79 | PDE10A (0.47) | ALDH1A1LMNASMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL18212597 | 0.79 | ADORA2A (0.49) | ALDH1A1LMNASMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL9139506 | 0.79 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL9193977 | 0.79 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL29474423 | 0.79 | ADORA1 (0.46) | ALDH1A1LMNASMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL125883 | 0.79 | ADORA1 (0.46) | ALDH1A1LMNASMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL4897046 | 0.79 | ADORA1 (0.46) | ALDH1A1LMNASMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL22956026 | 0.79 | CYP2A6 (0.49) | ALDH1A1LMNASMN1; SMN2MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831600-B | The preparation method of 3- phenyl -4-6- dichloro-pyridazine | 常州沃腾化工科技有限公司 | 2019-04-12 | — | — | CN | claimed |
| CN-106831600-A | The preparation method of the dichloro-pyridazine of 3 phenyl 46 | 常州沃腾化工科技有限公司 | 2017-06-13 | — | — | CN | claimed |
| CN-104292168-B | A kind of preparation method of 3-phenyl-4-hydroxyl-6-chlorine pyridazine | SHANDONG HUASHENG CHEMICAL CO., LTD. (CN) | 2016-01-13 | — | — | CN | claimed |
| CN-104292168-A | Preparation method of 3-phenyl-4-hydroxy-6-chloropyridazine | SHANDONG HUASHENG CHEMICAL CO LTD | 2015-01-21 | — | — | CN | claimed |
| US-12544373-B2 | Treatment of cancer, inflammatory diseases and autoimmune diseases | USHER III INITIATIVE, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4178580-B1 | BF 844 FOR USE IN THE TREATMENT OF CANCER | USHER III INITIATIVE INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20240279229-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-4178580-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | Usher III Initiative, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| EP-3307742-B1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-5462914-A | Reacting a hydroxypyridazine salt with a cyanogen halide | SANDOZ LTD. (CH) | 1995-10-31 | — | — | US | disclosed |
| EP-0556647-A1 | N-cyanopyridazinones as herbicides | SANDOZ LTD. (CH) | 1993-08-25 | — | — | EP | disclosed |
| CN-1075477-A | N-cyanopyridazinones having herbicidal activity | AGROLINZ AGRARCHEMIKALIEN (AT) | 1993-08-25 | — | — | CN | disclosed |
| EP-0095569-B1 | PROCESS FOR THE PREPARATION OF PHENYLPYRIDAZINE COMPOUNDS | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1987-01-28 | — | — | EP | disclosed |
| US-4478999-A | Process for the preparation of phenylpyridazine compounds | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1984-10-23 | — | — | US | disclosed |
| EP-0095569-A2 | Process for the preparation of phenylpyridazine compounds | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1983-12-07 | — | — | EP | disclosed |
| US-3953445-A | HERBICIDES | CHEMIE LINZ AKTIENGESELLSCHAFT (OE) | 1976-04-27 | — | — | US | disclosed |
| US-3932405-A | HERBICIDES | CHEMIE LINZ AKTIENGESELLSCHAFT (OE) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279229-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | ALDH1A1 4128/4885LMNA 413/4885SMN1; SMN2 21/4885 |
| US-12544373-B2 | Treatment of cancer, inflammatory diseases and autoimmune diseases | BRCA1, TP53, BCCIP | ALDH1A1 1382/4885LMNA 2410/4885SMN1; SMN2 62/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | ALDH1A1 442/4885LMNA 4227/4885SMN1; SMN2 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.